| Document |
Document Title |
|
WO/2024/035688A1 |
Described are the compounds, compositions and methods of treating diseases and disorders that involve aberrant B-cell lymphoma 6 (BCL6) activity.
|
|
WO/2024/031242A1 |
A method for synthesizing an aryl benzyl thioether compound using photocatalysis. By using the iron (III) complex [HIMXy Me][FeBr 4]([HIMXy Me]=l,3-bis(4-methoxy-2,6-dimethylphenyl)-4,5-dimethylimidaz
olium cation) as a catalyst, fac-Ir(...
|
|
WO/2024/035921A1 |
This disclosure relates to compounds which are degraders of son of sevenless homolog 1 (SOS1) and their use in treating cancers, in particular KRAS-mutant cancers.
|
|
WO/2024/027767A1 |
The present invention relates to a herbicide composition comprising a uracil compound comprising at least one carboxylate fragment represented by formula (I) and at least one herbicide active compound, and a use of the herbicide composit...
|
|
WO/2024/030429A1 |
Various novel nucleoside analogs described herein have the promise of achieving higher efficiency against a variety of viral infections, including the dangerous respiratory ones, like SARS-CoV-2 and COVID-19, as well as lower incidence a...
|
|
WO/2024/027814A1 |
Disclosed are a compound as represented by formula (I) having a KRas G12D inhibitory effect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the use thereof in the preparation of a drug for KRas G12D-related...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/027765A1 |
The present invention relates to the field of pesticides and herbicides, in particular to a method for preparing compound 2-chloro-4-fluoro-5-(3-methyl-2,6-dioxo-4-(trifluoromethyl)-
3,6-dihydropyrimidin-1(2H)-yl)benzoate of formula (I)....
|
|
WO/2024/025991A1 |
A method is disclosed of detecting a disease associated with pulmonary vascular remodeling in a subject. The method can comprise administering to the subject a compound of Formula I or Formula II. The method can further comprise imaging ...
|
|
WO/2024/022998A1 |
The present invention provides crystal forms of daprodustat, which are cocrystals comprising daprodustat free acid and a daprodustat pharmaceutically acceptable metal salt, wherein the metal salt is an alkali metal salt. The invention al...
|
|
WO/2024/026424A1 |
The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usefu...
|
|
WO/2024/020170A1 |
Provided herein are compounds which can act agonists of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating inflammatory and autoimmune diseases and disorders, such as diseases or disorders of the gastr...
|
|
WO/2024/018394A1 |
The present invention relates to a process for the preparation of crystalline form A of N, N'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride (I).
|
|
WO/2024/017251A1 |
The present disclosure relates to a macrocycle for inhibiting and inducing EGFR degradation and a preparation method for and a use of the macrocycle. Specifically, the present disclosure relates to a macrocycle as shown in general formul...
|
|
WO/2024/017258A1 |
Disclosed in the present invention are a multi-target small molecule inhibitor, a pharmaceutical composition containing same, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I)....
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/014303A1 |
Provided is a compound represented by formula (1).
|
|
WO/2024/012554A1 |
The present disclosure belongs to the field of biomedicine, and specifically relates to a method for preventing or treating neurodegenerative diseases or alleviating symptoms of neurodegenerative diseases. Said method comprises administe...
|
|
WO/2024/015918A2 |
The present disclosure provides novel chemotypes, pharmaceutical compositions thereof, and method of use thereof for treating parasitic infection, including infection caused by parasitic flatworms. The present compounds may be useful as ...
|
|
WO/2024/010015A1 |
Compounds represented by general formula (1), the compounds having strong inhibitory action against mPGES-1 and being useful as active ingredients for pharmaceuticals for the treatment of inflammation and the like.
|
|
WO/2024/010782A1 |
Disclosed are compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W arc as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a pr...
|
|
WO/2024/011075A2 |
A light delivery device for delivering light therapy includes a light source configured to emit light, one or more first piercing members extending from a distal surface of the light delivery device, the one or more first piercing member...
|
|
WO/2024/009691A1 |
The present invention provides: a nonaqueous electrolyte solution which comprises (I) at least one compound that is selected from the group consisting of compounds represented by general formula (1), compounds represented by general form...
|
|
WO/2024/008191A1 |
Provided are a quinazolinedione-containing compound with a structure represented by formula (I), a method for preparing same, and use thereof. The compound has excellent herbicidal activity against weeds in bulk crops such as rice and wh...
|
|
WO/2024/003535A2 |
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...
|
|
WO/2024/000401A1 |
The present invention relates to compounds of formula (I) preferred compounds are e.g. 2-((l-(4-oxo-3,4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives of formula (ll-A) an exemplary compound is e.g. 2-((l-(2-(isoindolin-2-yl...
|
|
WO/2024/003259A1 |
The present invention covers heterocyclic compounds of general formula (I): Formula (I), wherein (I'), Formula (I') represents a heterocyclic ring, said compound of general formula (I) being selected from the group consisting of: Formula...
|
|
WO/2023/247563A1 |
A compound of formula (I-A), R1 in each occurrence is selected from H, optionally substituted C1-12 alkyl and optionally substituted C6-20 aryl; R2 in each occurrence is selected from optionally substituted C1-12 alkyl and optionally sub...
|
|
WO/2023/249970A1 |
The present disclosure provides certain bifunctional compounds containing pyrimidine deriviatives that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of d...
|
|
WO/2023/244639A1 |
The present disclosure relates to methods of treating cancer in a subject, comprising analyzing one or more biological sample(s) for the presence of a first genetic marker and administering an EGFR inhibitor to the subject if the presenc...
|
|
WO/2023/243677A1 |
The present invention provides a plant disease control method having an excellent efficacy for controlling plant diseases, the method comprising treating plants or soil used for plant cultivation with a compound represented by formula (I...
|
|
WO/2023/244599A1 |
The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use th...
|
|
WO/2023/241608A1 |
The present application relates to compounds of formula (I) and formula (1'), which are useful as inhibitors of CSF-1R in the treatment of various diseases.
|
|
WO/2023/244713A1 |
The invention provides novel quinazoline derivatives, substituted at the C4 position with an unsubstituted or substituted, 3- to 10-membered monocyclic, bicyclic or bridged nitrogen heterocyclic ring moiety, that are shown to be potent a...
|
|
WO/2023/239675A1 |
The present disclosure is related to STING agonists, pharmaceutical compositions thereof, and the use of the agonists and pharmaceutical compositions to induce a STING-mediated immune response and/or to treat diseases and disorders media...
|
|
WO/2023/236752A1 |
Disclosed in the present invention are a heterocyclic derivative having a structure as shown in formula (I), or a stereoisomer and a pharmaceutically acceptable salt thereof. The heterocyclic derivative or the stereoisomer thereof has hi...
|
|
WO/2023/240084A2 |
The present disclosure relates generally to small molecule inhibitors of Sterile Alpha and TIR Motif containing 1 (SARM1) protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomer...
|
|
WO/2023/239710A1 |
Novel PI3K inhibitors of the general Formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, wherein R1 to R8 are as de...
|
|
WO/2023/231826A1 |
Disclosed in the present invention are a letermovir intermediate compound, and a preparation method and application thereof. In particular, disclosed are compounds (II), (III) and (IV), and the structures of the compounds are shown below...
|
|
WO/2023/232507A1 |
A process for increasing the yield of a process for the preparation of Compound (I), in which Compound (I) is obtained in solubilized form in an organic solvent phase, crystallized and separated from the mother liquor, comprising (I) STE...
|
|
WO/2023/230500A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds (I) that are inhibitors for spleen tyrosine kinase (Syk), which is a key signaling...
|
|
WO/2023/226920A1 |
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK inhibitors, which can be used for treating ...
|
|
WO/2023/227721A1 |
The present invention concerns novel crystalline forms of aprocitentan sodium salt, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crys...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/226456A1 |
The present invention relates to a method for preparing azoxystrobin. In the method of the present invention, azoxystrobin is prepared under catalysis by using a pentacyclozole compound or a salt thereof as a catalyst, wherein the pentac...
|
|
WO/2023/226323A1 |
The present invention relates to the technical field of chemical medicine, and in particular to a quinazoline derivative, and a preparation method therefor and the use thereof. The quinazoline derivative provided by the present invention...
|
|
WO/2023/220831A1 |
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kina...
|
|
WO/2023/224413A1 |
The present specification provides a heterocyclic compound, an organic light-emitting element comprising same, and a composition for an organic layer of an organic light-emitting element.
|
|
WO/2023/220572A1 |
The present invention is generally directed to inhibitors of protein tyrosine phosphatase enzymes (PTPN1 and/or PTPN2) useful in the treatment of diseases and disorders modulated by said enzymes and having the Formula (I). Further disclo...
|
|
WO/2023/218933A1 |
The present invention addresses the problem of providing a photoelectric conversion element which has excellent quantum efficiency when receiving blue light, an imaging element, a photosensor, and a compound. This photoelectric conversio...
|
